BMY vs LYEL
BMY: A leading biopharmaceutical innovator focused on discovering and delivering life-changing medicines to address serious illnesses globally. LYEL: Lyell Immunopharma is developing next-generation, engineered CAR T-cell therapies designed to provide durable, curative responses in hematologic and solid tumor cancers.
Side-by-side fundamentals
| Metric | BMY | LYEL | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $59.58 | $8.79 | |
| Market cap | $121.7B | $215M | |
| P/E as of 2026-10-08 | 13.12 | n/a | |
| Net margin FY2025, SEC XBRL | +14.6% | -762355.6% | BMY higher |
| Operating margin FY2025, SEC XBRL | n/a | -748344.4% | |
| ROE FY2025, SEC XBRL | +38.2% | -110.6% | BMY higher |
| ROA FY2025, SEC XBRL | +7.8% | -80.7% | BMY higher |
| Debt / equity as of 2026-09-03 | 1.93 | 0.00 | LYEL lower |
| Revenue growth (YoY) as of 2026-09-03 | +3.1% | -52.3% | BMY higher |
| Revenue CAGR (3y) SEC XBRL | +1.4% | -92.5% | BMY higher |
| Dividend yield as of 2026-09-03 | +4.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 19 | 0 | BMY higher |
| Beta as of 2026-09-03 | 0.25 | 1.31 | |
| 1-year return as of 2026-10-08 close | +33.8% | -51.9% | BMY higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.